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ABSTRACT
We examined the regulation of NF-κB in prostate cancer by estrogen receptor 
β (ERβ) based on the inverse correlation between p65 and ERβ expression that 
exists in prostate carcinomas and reports that ERβ can inhibit NF-κB activation, 
although the mechanism is not known. We demonstrate that ERβ functions as 
a gate-keeper for NF-κB p65 signaling by repressing its expression and nuclear 
translocation. ERβ regulation of NF-κB signaling is mediated by HIF-1. Loss of 
ERβ or hypoxia stabilizes HIF-1α, which we found to be a direct driver of IKKβ 
transcription through a hypoxia response element present in the promoter of the 
IKKβ gene. The increase of IKKβ expression in ERβ-ablated cells correlates with an 
increase in phospho-IκBα and concomitant p65 nuclear translocation. An inverse 
correlation between the expression of ERβ and IKKβ/p65 was also observed in the 
prostates of ERβ knockout (BERKO) mice, Gleason grade 5 prostate tumors and 
analysis of prostate cancer databases. These findings provide a novel mechanism 
for how ERβ prevents NF-κB activation and raise the exciting possibility that loss of 
ERβ expression is linked to chronic inflammation in the prostate, which contributes 
to the development of high-grade prostate cancer.
INTRODUCTION
Chronic inflammatory diseases are known to 
cause epithelial malignancies including prostate cancer 
[1, 2]. Recently, the Prostate Cancer Prevention Trial 
(PCPT) indicated that chronic intraprostatic inflammation 
influences the development of high-grade prostate cancer 
[3]. Therefore, understanding the mechanisms that 
contribute to chronic inflammation should facilitate the 
development of therapeutic approaches aimed at reducing 
the lethality of prostate cancer. Early studies revealed 
that ERβ signaling reduced systemic inflammation in 
some animal models [4, 5]. More recently, it was reported 
that ERβ-selective agonists can inactivate microglia and 
invading T cells by down regulating the expression of 
NF-κB [6]. Although cross-talk between ERβ and NF-κB 
is evident [7], the mechanism by which ERβ regulates 
the NF-κB pathway has not been resolved. In the resting 
stage of the canonical NF-kB pathway, the heterodimeric 
complex of RelA (p65) and p50 is sequestered in the 
cytoplasm in association with IκBα and is inactive. 
Once activated by external stimuli such as cytokines, 
lipopolysaccharide or viruses, IκB kinases (IKKβ) 
phosphorylate IκBα, which is degraded by the proteasome 
[8]. This cascade event allows the translocation of the 
p65.p50 complex to the nucleus where it regulates the 
transcription of its target genes. The key question is how 
does ERβ impact this process of NF-κB activation?
Work from our laboratory has established an 
important mechanistic link between ERβ and HIF-1. 
Specifically, we demonstrated that ERβ promotes the 
proteasomal degradation of HIF-1α by sustaining the 
expression of prolyl hydroxylase 2 (PHD2) [9, 10]. 
Consequently, loss of ERβ or function results in HIF-
1α stabilization and HIF-1-mediated transcription. There 
is a functional link between the expression of HIF-1α 
and p65 in several cancers [11, 12], which is consistent 
with the fact that hypoxia and inflammation are common 
features of all solid tumors [13]. For these reasons, we 
examined the hypothesis that ERβ repression of the 
NF-kB pathway involves HIF-1α. Our data reveal that 
ERβ functions as a repressor of HIF-1α-mediated NF-
kB activation and support the possibility that ERβ may 
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contribute to the prevention of chronic inflammation in 
the prostate and prostate cancer.
RESULTS
Loss of ERβ promotes p65 expression and NF-κB 
activation
Loss of ERβ promotes an EMT in PNT1a cells, 
which are immortalized prostate epithelial cells [9]. 
Interestingly, we observed that ERβ-ablated PNT1a cells 
express high levels of p65 (both protein and mRNA) 
compared to control cells (shGFP) (Figure 1A and 1B). To 
substantiate the link between ERβ and p65, we exposed 
these cells to hypoxia, which diminishes ERβ expression 
[10]. As shown in Figure 1C, p65 expression is increased 
in hypoxic conditions with a concomitant decrease in 
ERβ. We next assessed NF-κB activation using an NF-κB 
luciferase reporter construct, which contains 4 copies of 
an NF-kB binding site. There was a greater than 2 fold 
increase in luciferase activity in both ERβ-ablated and 
hypoxic cells compared to their respective controls (shGFP 
and normoxic cells) (Figure 1D). These data indicate 
that ERβ regulates p65 expression and its activation. To 
understand the mechanism by which ERβ regulates p65 
expression, we focused on HIF-1 because it can induce 
p65 expression [14]. HIF-1α is stabilized in ERβ-ablated 
PNT1a cells [9] resulting in an increase in p65 expression 
and its target gene, Bcl-2 (Figure 1E). More importantly, 
knocking-down HIF-1α in ERβ-ablated cells decreased 
p65 expression (Figure 1F).
Loss of ERβ promotes p65 nuclear translocation
Given that the nuclear localization of p65 is 
associated with high Gleason grade prostate cancer 
[15, 16], we examined the relationship between p65 
localization and ERβ expression in ERβ-ablated PNT1a 
cells. Immunofluorescence staining indicated that p65 is 
localized exclusively in the cytoplasm of control cells 
(shGFP) and in the nuclei of ERβ-ablated cells (shERβ) 
(Figure 2A). The notion that loss of ERβ promotes p65 
Figure 1: ERβ represses p65 expression and NF-κB activation. Comparison of p65 protein A. and mRNA expression B. in 
control (shGFP) and ERβ-depleted PNT1a cells (shERβ-1 and shERβ-2). C. PNT1a cells were maintained in either normoxia or hypoxia 
for 20–24 hours and the expression of ERβ, p65 and actin was assessed by immunoblotting. D. An NF-κB luciferase reporter construct 
was used to compare NF-κB transcriptional activity between control and ERβ-depleted PNT1a cells, and PNT1a cells maintained in either 
normoxia or hypoxia for 20–24 hours. Data represent the average of three separate experiments with SEM indicated. (*p value: < 0.05). 
E. The expression of HIF-1α, p65 and Bcl2 was assessed in control and ERβ-depleted PNT1a cells by immunoblotting. F. An shRNA that 
targets HIF-1α was expressed in ERβ-depleted PNT1a cells and the expression of HIF-1α, p65 and actin was assessed by immunoblotting.
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nuclear translocation is supported by the analysis of 
the prostates from ERβ knockout (BERKO) mice. This 
analysis revealed nuclear p65 localization in BERKO 
prostates that was not evident in the age-matched, wild-
type prostates (Figure 2B). Furthermore, an inverse 
correlation between the expression of ERβ and HIF-
1α and p65 was detected by comparing normal prostate 
epithelial cells and PC3-M cells, which are an aggressive 
variant of PC3 cells [17] (Figure 2C). We also observed 
that diminishing PHD2 expression in PNT1a cells, which 
mimics the effect of ERβ loss and stabilizes HIF-1α 
[9], increased p65 expression (Figure 2D). A negative 
correlation between ERβ and p65 expression was also 
evident exists in a cohort of 87 human prostate tumors 
based on analysis of the cBioportal database (Figure 2E).
ERβ regulates p65 nuclear translocation via the 
IKKβ/IκBα canonical pathway
To understand how p65 nuclear translocation is 
regulated by ERβ signaling, we focused on the IKKβ/IκBα 
canonical pathway. Interestingly, an increase in IKKβ and 
p-IκBα expression was observed in ERβ-ablated PNT1a 
cells compared to control cells (Figure 3A). However, 
there was no difference in total IκBα expression. IKKβ 
mRNA levels were also elevated in ERβ-ablated cells 
compared to the control cells suggesting transcriptional 
regulation (Figure 3B). Hypoxia also increased the 
expression of both IKKβ and p-IκBα but not total IκBα 
(Figure 3C). The induction of IKKβ expression by hypoxia 
is specific because there was no change in the expression 
of IKKα and IKKγ (Figure 3D). Moreover, an increase in 
p-IκBα was observed when the cells were treated with a 
specific ERβ antagonist, PHTPP, supporting the possibility 
that the IKKβ/IκBα canonical pathway is regulated by 
ERβ (Figure 3E).
IKKβ transcription is regulated by HIF-1α
To demonstrate that the increase of IKKβ expression 
in ERβ-ablated cells is mediated by HIF-1α, we knocked 
down HIF-1α and observed a dramatic reduction in 
IKKβ compared to the control cells (Figure 4A). This 
observation prompted us to examine whether the promoter 
of IKKβ contains a HIF-1 binding site. We found such 
a binding site (ACGTG) located at -810 bp upstream of 
the transcription start site (Figure 4B). Therefore, we 
cloned the promoter region from -1000 bp to +20 bp in 
a luciferase reporter plasmid, which was used to transfect 
ERβ-ablated cells or hypoxic cells. A 2–3 fold induction 
Figure 2: Analysis of ERβ and p65 localization and expression in prostate cells and tissues. A. Control and ERβ-depleted 
PNT1a cells and B. Ventral prostates from 10 month old wild-type and BERKO mice were stained with a p65 antibody and DAPI to 
visualize nuclei, and analyzed by immunofluorescence microscopy. Scale bar: 50 μm. C. The expression of ERβ, HIF-1α and p65 was 
compared in PNT1a and PC3-M cells by immunoblotting. D. The expression of p65 was compared in control (shGFP) and PHD2-ablated 
PNT1a cells (shPHD2#1 and shPHD2#2) by immunoblotting. E. An inverse correlation between ERβ and p65 in a cohort of 82 prostate 
tumors was determined from analysis of the cBioportal database.
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of normalized luciferase activity was seen in these 
cells compared to their respective controls (Figure 4C) 
providing evidence that this site functions as a hypoxia 
response element (HRE). Moreover, mutating this HRE 
to AAATG (HREm) in the reporter gene abrogated the 
hypoxia-mediated luciferase induction (Figure 4D). These 
data indicate that the expression of IKKβ is driven by HIF-
1α in ERβ ablated cells.
Figure 3: Regulation of IKKβ and pIκBα expression by ERβ and hypoxia. A. The expression IKKβ, IκBα and pIκBα was 
compared in control and ERβ-depleted PNT1a cells by immunoblotting. B. The expression IKKβ mRNA was quantified in control and 
ERβ-depleted PNT1a cells by qPCR. C. PNT1a cells were maintained in either normoxia or hypoxia for 20–24 hours and the expression of 
HIF-1α, IKKb, IκBα pIκBα and actin was assessed by immunoblotting. D. PNT1a cells were maintained in either normoxia or hypoxia for 
20–24 hours and the expression of IKKα and IKKγ was assessed by immunoblotting. E. The expression of pIκBα was assessed in PNT1a 
cells that had been treated with vehicle alone (control) or the ERβ antagonist PHTPP for 18 hours.
Figure 4: HIF-1α regulates IKKβ transcription. A. The expression of HIF-1α and IKKβ was compared in control (shGFP), 
ERβ-depleted (shERβ) or ERβ-depleted PNT1a cells expressing a HIF-1α shRNA (shERβ/shHIF-1α) by immunoblotting. B. Schematic 
depicting a luciferase reporter construct containing a HIF-1 binding site in the IKKβ promoter. C. The reporter construct shown in B was 
used to compare IKKβ transcriptional activity between control and ERβ-depleted PNT1a cells. D. The oligonucleotide containing the 
hypoxia response element (HRE) as demonstrated in C was mutated from ACGTG to AAATG. Wild-type (wt) and HRE mutant (mut) 
reporter constructs were used to compare IKKβ transcriptional activity between control and ERβ-depleted PNT1a cells. Data represent 
three separate experiments with SEM indicated. (*p value: < 0.05).
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IKKβ expression is associated with high-grade 
prostate tumors
To assess whether an inverse correlation between 
ERβ and HIF-1α/IKKβ expression exists in prostate cancer, 
we compared their expression in Gleason grade 5 tumors 
and normal prostate epithelia by immunofluorescence 
staining. The H&E staining of these tissues is provided in 
Figure 5A. ERβ is expressed in normal epithelia but not in 
grade 5 tumors (Figure 5B) supporting our previous findings 
[10]. In marked contrast, high expression of IKKβ was 
observed in grade 5 tumors compared to normal epithelia 
(Figure 5C). A link between IKKβ and NF-κB activation in 
this context is indicated by our finding that knock-down of 
IKKβ expression in PC3-M cells, which exhibit properties 
of high-grade carcinoma, diminished p65 expression 
(Figure 5D). A negative correlation between ERβ and 
IKKβ expression was also evident in a cohort of 70 human 
prostate tumors based on analysis of the cBioportal database 
(Figure 5E).
DISCUSSION
The results presented in this study provide a 
mechanism for how loss of ERβ, which occurs in high-
grade prostate cancer, contributes to NF-κB activation. 
The core of this mechanism is that the loss of ERβ, 
which stabilizes HIF-1α [9], results in the HIF-1α 
mediated transcription of IKKβ and consequent nuclear 
translocation of p65 (Figure 6). These findings have 
important implications for development of chronic 
inflammation in prostate cancer and they highlight an 
unexpected anti-inflammatory role for the ability of ERβ 
to promote the degradation of HIF-1α.
Figure 5: Analysis of ERβ, HIF-1α and IKKβ expression in prostate tissues. A. H&E staining of normal prostate and primary 
Gleason grade 5 prostate carcinomas. B, C. These tissues were stained with antibodies specific for ERβ and IKKβ, counter-stained with 
DAPI to visualize nuclei, and analyzed by immunofluorescence microscopy. Scale bar: 50 μm. Six different specimens were examined with 
similar results. D. The expression of p65 was compared in control (shGFP) and IKKβ-ablated PC3-M cells (shIKKβ#1 and shIKKβ#2) by 
immunoblotting. E. An inverse correlation between the expression of ERβ and IKKβ was detected in a cohort of 65 prostate tumors was 
determined from analysis of the cBioportal database.
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Although many previous studies have described 
the ability of ERβ to inhibit NF-κB activation and 
reduce inflammation [4, 5], the specific mechanisms 
involved are less clear. Our functional characterization 
of a hypoxia responsive element (HRE) in the promoter 
of the IKKβ gene and demonstration that HIF-1α drives 
IKKβ transcription directly via this HRE provides such 
a mechanism. This mechanism is intimately associated 
with ERβ because it de-stabilizes HIF-1α [9, 10] and, 
consequently, prevents NF-kB activation. Interestingly, 
loss of ERβ had no effect on IKKα expression even 
though both IKKα and IKKβ phosphorylate IκBα [8]. 
A worthwhile question to pursue based on our findings is 
whether the ability of ERα to suppress NF-κB activation, 
which occurs in breast cancer [18], involves a similar 
mechanism. A contribution of ERα to NF-kB regulation 
is unlikely in the prostate, however, because ERα is not 
expressed in prostate epithelial or carcinoma cells.
The mechanism of NF-kB regulation by ERβ that 
we describe is likely to be one component of a more 
complex set of interactions. Specifically, there is evidence 
that IKKβ and NF-kB can promote HIF-1α transcription 
[11, 12]. This finding implies that a positive feedback loop 
involving HIF-1 and NF-kB exists, and that this feedback 
loop is under the repressive control of ERβ. Indeed, given 
the potential impact that this feedback loop can have on 
cells, the ability of ERβ to inhibit it becomes a critical 
regulatory event for preventing the consequences of 
HIF-1- and NF-kB-mediated transcription. There is also 
evidence that that a variant of ERβ, ERβ2, which lacks 
the ability to bind ligand and activate canonical ERβ 
gene expression, can interact with and stabilize HIF-1α 
in normoxic environments [19]. This finding is relevant to 
our work because ERβ2 is expressed in aggressive prostate 
cancers and it may contribute to the HIF-1/NF-kB positive 
feedback loop.
Our findings provide a possible mechanism for the 
increased NF-κB activation that is associated with high 
Gleason grade prostate tumors because these tumors also 
exhibit loss of ERβ and induction of HIF-1α expression 
[10]. This connection is very significant in light of the 
reports that chronic inflammation is associated with high-
grade prostate cancer [20]. The link between loss of ERβ 
and chronic inflammation may also be relevant for more 
differentiated prostate tumors. Recently, we demonstrated 
that prostate tumors with a primary Gleason score of 3 
are heterogeneous for ERβ expression. [21]. An interesting 
question going forward is whether grade 3 tumors that 
exhibit loss of ERβ are more inflammatory than those 
tumors that express ERβ. In pursuit of the mechanism 
involved, we discovered that tumors that were deficient 
in ERβ expression also exhibited loss of PTEN and that 
PTEN loss had a causal role in repressing ERβ [21]. It is 
worth noting in this context that PTEN loss promotes NF-
κB activation in pancreatic ductal carcinoma [22] and loss 
of ERβ could be a critical factor in this activation.
MATERIALS AND METHODS
Cells and reagents
PNT1a cells were obtained from M. Littmann 
(Baylor College of Medicine, Houston). The human 
prostate cancer cell line, LNCaP was obtained from 
American Type Culture Collection (ATCC). PC3-M 
cells were obtained from R. C. Bergan (Northwestern 
Figure 6: Schematic summarizing the major conclusion of the study. We propose that ERβ functions as a gate-keeper of NF-κB 
activation by preventing the HIF-1-mediated activation of the IKKβ/pIκBα axis.
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University, Chicago). 3β-androstane-diol (3β-Adiol) and 
PHTPP experiments were performed by incubating cells 
with 3β-Adiol (5 μM; Sigma) or PHTPP (10 μM; Tocris) 
for 2–3 days. The generation of ERβ-ablated PNT1a cells, 
PHD2-ablated PNT1a cells and HIF-1α ablated cells has 
been described previously [9]. IKKβ ablated PC3-M 
cells were generated using shRNAs (Open Biosystems; 
TRCN0000018918 and TRCN0000018919). Stable cell 
transfectants were generated by puromycin or hygromycin 
selection (0.5 μg/mL for PNT1a and 2 μg/mL for PC3-M 
cells). The resultant ERβ, HIF-1α-ablated cells were used 
for subsequent experiments. For experiments involving 
hypoxia, cells were incubated with 100 μM cobalt chloride 
for 22–24 hours.
Biochemical analyses
For immunoblotting, the following Abs were used 
p65, IKKα, IKKβ, IKKγ (Santa Cruz), HIF-1α (Novus) 
and β-actin (Sigma). Immune complexes were detected 
using enhanced chemiluminescence (ECL; Pierce). For 
quantitative real-time RT-PCR (qPCR), total RNA was 
extracted from cells using the TRI reagent (Sigma) and was 
reverse transcribed using reverse transcription reagents 
(Applied Biosystems) and analyzed by SYBR Green 
Master (Roche) using a real-time PCR system (ABI; Prism 
7900HT Sequence Detection system). The expression of 
target genes was normalized to 18s RNA and analyzed 
by the comparative cycle threshold method (DDCt). For 
luciferase assays, PC3-M cells were transfected with the 
desired plasmids and a Renilla luciferase construct to 
normalize for transfection efficiency. Luciferase assays 
were performed using Dual Glo luciferase assay system 
(Promega). Relative luciferase activity was calculated as 
the ratio of firefly luciferase to Renilla luciferase activity.
Transgenic mice
ERβ knockout (BERKO) mice were generated by 
the Korach laboratory [23] and were purchased from The 
Jackson Laboratory. The knockout allele was maintained 
on a C57BL/6 background. The mice were used in 
these studies were 10 months old. Sections from these 
prostates and age-matched controls were processed for 
immunostaining as described below.
Immunofluorescence staining
Murine prostate specimens from transgenic mice 
(see above) and human prostate cancer specimens, which 
were obtained from the Tissue Bank at the University 
of Massachusetts Medical School, were fixed in 
paraformaldehyde (4%), embedded in paraffin, sectioned 
(5 μM) and used for hematoxylin and eosin (H&E) and 
immunofluorescence staining. After antigen unmasking, 
the specimens were incubated in 10% serum in PBS for 
30 minutes, washed for 3 min in PBST, and incubated 
with rabbit polyclonal p65 antibody (Santa Cruz), rabbit 
polyclonal IKKβ antibody (Santa Cruz) or HIF-1α 
monoclonal antibody (Novum) overnight at 40C. The slides 
were washed 5 min with PBST and incubated 45 minutes 
in a dark chamber with the fluorochrome-conjugated 
secondary antibody (goat anti-rabbit conjugated Alexa 
Fluor 488, Life Sciences A-11008). Slides were washed 
and counterstained in the dark with DAPI (Invitrogen) 
for 10 minutes, washed with three changes of PBST and 
mounted under coverslips with aqueous mounting medium 
(Thermo Electron corp. Pittsburgh, PA). Results were 
analyzed using an LSM 710 Meta confocal microscope 
(Carl Zeiss MicroImaging Gmbh, Munich, Germany).
Statistical analysis
Data are presented as the mean from three separate 
experiments ± SD. The Student t test was used to determine 
the significance of independent experiments. The criterion 
P < 0.05 was used to determine statistical significance.
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